Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
Nishanth E. Sunny, Fernando Bril, Kenneth J. Cusi · Trends in Endocrinology and Metabolism · 2016
Cited by 319 works. doi:10.1016/j.tem.2016.11.006
Authors
References
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
- Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology